SCHEMBL3500430

SCHEMBL3500430

O=c1occcc1C=Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.47
NFE2L2 Q16236 3/20 0.47
TRPA1 O75762 2/20 0.47
ALDH1A1 P00352 4/20 0.44
MAPT P10636 2/20 0.44
F2 P00734 1/20 0.44
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
MAOA P21397 1/20 0.42
DPYD Q12882 1/20 0.42
NR1H2 P55055 1/20 0.41
BRD4 O60885 1/20 0.40
CREBBP Q92793 1/20 0.40
CA1 P00915 1/20 0.40
CA9 Q16790 1/20 0.40
ELANE P08246 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(Z)-1,2-Diphenylethene SCHEMBL28428310 0.78 CA1 (0.70) MAOBNFE2L2TRPA1ALDH1A1MAPT
SCHEMBL10582579 0.76 CA1 (0.34) ALDH1A1MAPTF2NPC1POLB
SCHEMBL29849865 0.76 NFE2L2 (0.46) MAOBNFE2L2TRPA1ALDH1A1MAPT
SCHEMBL10582572 0.76 CA1 (0.34) ALDH1A1MAPTF2NPC1POLB
SCHEMBL44502 0.73 NFE2L2 (0.68) MAOBNFE2L2TRPA1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL7653150 0.73 NFE2L2 (0.68) MAOBNFE2L2TRPA1MAOAMEN1
SCHEMBL44503 0.73 NFE2L2 (0.68) MAOBNFE2L2TRPA1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL7653143 0.73 NFE2L2 (0.68) MAOBNFE2L2TRPA1MAOAMEN1
SCHEMBL6360540 0.73 NFE2L2 (0.68) MAOBNFE2L2TRPA1MAOAMEN1
SCHEMBL9540538 0.73 NFE2L2 (0.68) MAOBNFE2L2TRPA1MAOAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702039-A1 METHOD OF PRODUCING STYRYLPYRONES AND CHALCONES Nicoventures Trading Limited (GB) 2026-03-04 EP claimed
WO-2024224080-A1 METHOD OF PRODUCING STYRYLPYRONES AND CHALCONES Nicoventures Trading Limited (GB) 2024-10-31 WO claimed
CN-111333661-A Phenylpyrone derivative of Phellinus ribis, and preparation method and application thereof 吴浩然 2020-06-26 CN claimed
US-20260085054-A1 DERIVATIVE OF HISPIDIN FROM SANGHUANGPORUS SANGHUANG, AND PREPARATION METHOD AND USE THEREOF UNIV CHINA THREE GORGES CTGU (CN) 2026-03-26 US disclosed
US-20260085054-A1 DERIVATIVE OF HISPIDIN FROM SANGHUANGPORUS SANGHUANG, AND PREPARATION METHOD AND USE THEREOF UNIV CHINA THREE GORGES CTGU (CN) 2026-03-26 US disclosed
EP-4702038-A1 METHOD OF PRODUCING POLYPHENOLS Nicoventures Trading Limited (GB) 2026-03-04 EP disclosed
EP-4702039-A1 METHOD OF PRODUCING STYRYLPYRONES AND CHALCONES Nicoventures Trading Limited (GB) 2026-03-04 EP disclosed
CN-121517382-A Hispidin derivative in Phellinus linteus and preparation method and application thereof 三峡大学 2026-02-13 CN disclosed
CN-120004837-A Phellinus pyranone compound Interfungin A, separation and purification method of compound and application of compound as anticancer drug 浙江省农业科学院 2025-05-16 CN disclosed
CN-114573539-B Method for preparing compound Phellibaumin D from phellinus linteus medicinal material 中国科学院大连化学物理研究所 2024-11-05 CN disclosed
WO-2024224080-A1 METHOD OF PRODUCING STYRYLPYRONES AND CHALCONES Nicoventures Trading Limited (GB) 2024-10-31 WO disclosed
WO-2012126789-A1 PRODUCTION OF CHLOROGENIC AND DACTYLIFRIC ACID SPECIES NESTEC S.A. (CH) 2012-09-27 WO disclosed
CN-102238956-A Combination therapy comprising kiwifruit and steroids and uses thereof EFFICAS INC 2011-11-09 CN disclosed
EP-2249849-A1 COMBINATION THERAPY COMPRISING ACTINIDIA AND STEROIDS AND USES THEREOF Efficas, Inc. (US) 2010-11-17 EP disclosed
US-20100111927-A1 Compositions Comprising Actinidia and Methods of Use Thereof KIM SUNYOUNG 2010-05-06 US disclosed
WO-2009091915-A1 COMBINATION THERAPY COMPRISING ACTINIDIA AND STEROIDS AND USES THEREOF EFFICAS, INC. (US) 2009-07-23 WO disclosed
CN-101291679-A Compositions comprising actinidia and methods of use thereof EFFICAS INC PANGENOMICS CO LTD (US) 2008-10-22 CN disclosed
US-20080175888-A1 Combination Therapy Comprising Actinidia and Steroids and Uses Thereof EFFICAS, INC. 2008-07-24 US disclosed
EP-1858535-A2 COMPOSITIONS COMPRISING ACTINIDIA AND METHODS OF USE THEREOF Efficas, Inc. (US) 2007-11-28 EP disclosed
WO-2006093793-A2 COMPOSITIONS COMPRISING ACTINIDIA AND METHODS OF USE THEREOF EFFICAS, INC. (US) 2006-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085054-A1 DERIVATIVE OF HISPIDIN FROM SANGHUANGPORUS SANGHUANG, AND PREPARATION METHOD AND USE THEREOF SDHA, HRH2, SDHB MAOB 1516/4885NFE2L2 3049/4885TRPA1 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.